The Starfish Project

The combined effort of our whole family.

Archive for the ‘Vitamin C IVs’ Category

Hoffer’s Orthomolecular Treatment of Cancer

leave a comment »

Written by:  Abram Hoffer, PhD, MD, FRCP(C)

Abram Hoffer, PhD, MD

Abram Hoffer, PhD, MD

Between 1978 and March, 1999 I have seen over 1040 patients suffering from cancer who came to me for nutritional and psychiatric counseling. This is no longer a surprising combination as it was when I first started to practice psychiatry in 1952. I attended my first annual meeting of the American Psychiatric Association in Los Angeles, in 1952. I did not meet another psychiatrist there with a PhD in Biochemistry. Since then many more scientists with the double degrees have become active in this field but of these very few actively pursue this particular combination. Orthomolecular theory and practice drives these two together. I have retained my interest in the biochemistry and clinical aspects of nutrition combining this with my education in medicine and later in psychiatry. The recovery of my first patient in 1960 from terminal bronchiogenic cancer of the lung arose from this coalescence of these two disciplines.

 By 1960 my research group in Saskatchewan had discovered the first biochemical substance that was clearly related to the schizophrenias. Not knowing its structure we called it the mauve factor until it was later identified as kryptopyrrole. We tested thousands of patients and found that over 75% of all schizophrenic patients excreted this substance in their urine. It was also present in about 25% of other psychiatric groups, in about 10% of severely stressed physically ill patients and in about 5% of normal people but they were mostly first order relatives of schizophrenic patients. It disappeared with recovery of the patients no matter how they were treated. I was particularly interested in the fact that out of eight patients with cancer of the lung this factor was present in 5.

In 1960 a retired psychotic professor was admitted to our psychiatric department at University Hospital in Saskatoon. He had a bronchiogenic carcinoma of the lung and when he became psychotic it was concluded he had secondaries in his brain. He was placed on terminal care, expected to die in a month or so. Earlier he had been discharged to the care of his wife and a nurse but after several weeks had to be readmitted since they could not cope with his behavior. As soon as I discovered he was on our ward I had his urine collected and we tested it for the factor. He excreted copious quantities which we were able to use to help us identify the substance. I then advised his resident to start him on niacin 1 gram after each meal and on ascorbic acid 1 gram after each meal. By then I knew that this combination of vitamins used in megadoses was very helpful in treating any patient with this factor in their urine no matter what they were diagnosed. Fortunately for this patient the resident accepted my advice (the patient was not under my care but I was Director of Psychiatric Research at the hospital). He was started on the two vitamins on Friday afernoon and he was mentally normal by the following Monday.

I knew this patient before he became ill as I had treated his wife. After he had recovered I advised him to remain on these two vitamins. In 1960 our research unit was the only one in Canada, and perhaps in the world, where 500 mg tablets of these vitamins were available. They were specially made for us. If smaller tablets were used in these large doses they would make our patients sick because they contained so much filler. I told him that if he would pick up a supply each month I would give it to him free. This meant he had to see me each month and this gave me the opportunity of assessing his psychiatric state. I did not expect he would recover from his cancer. He had been told of his dismal prognosis and I did not contradict that. To my surprise he kept on coming back. About 12 months later I had lunch with the Director of the Cancer Clinic which had been following his case. He told me that the tumor had become less and less visable with each X ray every three months and that it was now no longer present. He lived about 30 months after he was diagnosed terminal. I had hoped that when he died he would be autopsied at University Hospital. Unfortunately he died at another hospital and I did not hear this until several days later. He did not die from his cancer.

Two years later a woman I had treated for depression several years earlier consulted me again. This time she was depressed because her 16-year-old daughter had Ewings tumor (a highly malignant sarcoma) in one arm and she was slated for surgery to amputate her arm. This was the standard treatment. I told her about the previous patient and his recovery and suggested that although there was no evidence it would help it could do no harm and might possibly be of some value. Her daughter agreed to take niacinamide 1 gram after each meal and ascorbic acid 1 gram after each meal. Her surgeon agreed to postpone surgery for a month. She recovered and the last time I heard from her family she was married and leading a normal productive life, with both arms. I concluded that vitamin B-3 was the most important component and that the vitamin C was helpful. In Saskatchewan under my direction we did the first double blind controlled therapeutic trials in Psychiatry, completing six by 1960. Therefore I was aware of the powerful influence of placebo. However when two terminal patients recovered on the vitamins it became powerful evidence that there was more than placebo at work.

I did not see any more cancer patients until 1977 after I had established my practice in Victoria, BC. In British Columbia specialists will not accept patients until they have been referred by their general practitioners. As a psychiatrist I saw patients referred with psychiatric problems but in most cases the referring physicians would not indicate why the referral had been made and I would only discover the reason when I finally saw my patient.

A.S.An elderly woman appeared and when I asked her why she had come she replied that she had cancer of the head of the pancrease. She had developed jaundice. Her surgeon discovered she had a large tumor in the head of the pancreas which occluded her bile duct. He promptly closed, created a by-pass, and when she recovered from the anesthesia advised her that she had about 3 to 6 months to live. She worked in a book store. She had read Norman Cousins book Anatomy of an Illness and thought that if he was able to take so much vitamin C with safety she could too and she began to take 10 grams each day. The next time she consulted her doctor she told him what she was doing. He referred her to me since he was familiar with my interest in megadoses of vitamins. I reviewed her program and increased her vitamin C to 4o grams daily trying to reach the sublaxative level. I had been using multi nutrients for my schizophrenic patients for many years and since I had no idea which, if any, of these vitamins might help I reasoned that she would have a much better chance if she also were to take more than one nutrient. I then added vitamin B-3, selenium, and zinc sulfate. Six months later she called me at home in great excitement. She had just had a CT scan. No tumor was visible. The CT scan was repeated by the incredulous radiologist. Her original bile duct had reopened and now she had two. She remained alive and well until she died February 19, 1999, nearly 22 years after she was told she would die.

Rarely patients make a major contribution to medicine by their interest in a disease and their willingness to try innovative approaches. A.S’s recovery changed my professional career and I believe will make a major contribution to the complementary treatment of all cancer patients. Last year at a public meeting I thanked her publicly when I discussed her case before a meeting of Cancer Victors. She added that I had changed her life as well. She has also changed the life of hundreds of cancer patients who became victors, not victims.

By telling her friends, relatives and customers about her recovery she changed the nature of my practice. That first year another five patients were referred. The second case was a man with a sarcoma of the prostate which was invading his pelvic bone. He was advised no treatment was available. His doctor referred him to me and I started him on a similar program. But he was only able to take about 10 grams of vitamin C daily. I asked his doctor if he would mind injecting him with 10 grams of vitamin C twice weekly. After six months his doctor wanted to know how much longer would he need to receive his vitamin C. He told me that the tumor was gone. He stopped the injection. He lived another 9 years and died at age 80, but not from his cancer.

More patients were referred to me each year. At first almost all of them were patient-generated and often it took remarkable persuasive powers for the patient to obtain the necessary referral. After assessing their physical and mental state I would talk to them about the therapeutic regimen. I outlined the program in detail describing each nutrient and why I thought they might be helpful. I added that there was no guarantee that the vitamins would be helpful but gave them hope by describing the cases who had had a dramatic response. I added that the vitamin mineral program would decrease the toxicity of the xenobiotic treatment and would increase the efficacy of the xenobiotic program. If they needed surgery they would heal faster afterwards. If they needed chemotherapy the program would make it more tolerable and less painful and if they needed radiation the program would decrease the intensity of the side effects of the radiation and increase its efficacy. These comments were based on the literature which was developing rapidly. The program was designed to assist the body in controlling the cancer and was not a direct assault on the tumor. The attack on the tumor was carried out by the other physicians including their family doctor, the surgeons, the radiologist and oncologists. The diagnosis of the cancer and the xenobiotic treatment used was left entirely to the patient and their other doctors. I did not advise them whether or not they should take any other treatment. Very few did not receive xenobiotic therapy. After describing the program I would arrange to see them once more unless they were very depressed and anxious, in which case I would see them more often. A few of the patients had been under my care before they developed their cancer and I continued to see them. I then sent a consultation report to each referring physician. After the second interview they were returned to the care of their family physicians. I had not planned on doing any follow up but after several years when I had treated about 50 patients I became aware that the patients who had followed the regimen consistently for at least two months lived much longer than the patients who did not start the program or did not take it for at least two months.

About this time I went to a Festchrift for Dr. Arthur Sackler at Woods Hole, Mass. We met in 1951 when I was starting our research program. He and his brothers were practicing in mid-Manhatten. They were probably the first orthomolecular psychiatrists in the United States. They were treating schizophrenic patients by injecting them with histamine. After I returnd home I repeated their studies and found that their observations were correct. Out of twelve patients I treated using their regimen 8 became normal. The treatment was difficult since they had to be given increasing amounts of subcutaneous histamine until their diastolic pressure decreased to 0. It was amazing to see how comfortable they could be with that low blood pressure. Treatments were givern daily on week days until the series was completed. I did not continue this series because by this time I was using megadoses of vitamin B-3 which was much easier to administer and equally effective. The histamine flush was identical with the niacin flush. At that meeting Dr. Linus Pauling delivered a vigorous and careful critique of the Mayo Clinic’s attempt to repeat the studies he had done with Dr. Ewan Cameron in Scotland. The Mayo group claimed they had exactly repeated these studies but it was clear on reading their paper that they had not. Dr. Pauling did not object to their negatives findings. He objected to their statement that their conclusions resulting from a different method of administering the vitamin C were used to condemn his and Camerons findings. In other words no scientist can claim to confirm or deny any study unless they really have repeated the original work as described by the original authors.

Linus Pauling

Linus Pauling

The next morning, after breakfast, I visited Linus Pauling who was staying in the room next to mine. When I walked in he was busy with a hand calculator. He told me he was working out the electron orbitals saying that he did not understand them unless he did the calculations himself. I told him that on the basis of my fifty patients I had concluded that he and Cameron were right, that vitamin C in large doses did improve enormously the outcome of treatment for cancer. Linus asked me if I intended to publish the data. I replied that I did not. I added that in my opinion there was little point in trying to do so since it wold be impossible to gain entry into any medical journal, that they would not accept any paper that dealt favorably with megadose vitamin therapy. The New England Journal of Medicine, which had published the Mayo Clinic attack on Pauling, refused to publish his rebuttal. Linus urged me to do a complete follow up study of every patient I had treated. I was flattered and agreed that I would. He said that he would see that the material would be published. But when I returned home I decided not to do the follow up. It would have meant an enormous amount of work. I thought tht Dr. Pauling was being kind to me. Two years later I received a letter from Linus in which he said bluntly “Abram where is the study”. I decided that he was serious about it. By then I had seen 134 patients. I apologized and promised to start the follow up immediately. I traced every patient and determined whether they were alive, where they were, and what had happened to their lives. I contacted the patients, their famlies, their doctors, the cancer clinic where nearly all of them had been seen and treated. The Cancer Clinic in Victoria did a good job of investigation, diagnosis and treatment using only xenobiotic therapies.

Dr. Pauling developed an elegant method for determining the probable outcome of treatment using cohorts of patients who were or were not treated. After I had completed the follow up I sent the case histories, with identification of each patient removed, and the follow up study. We decided to use the duration of life as the only variable. This began when they first saw me and ended with the day of their death. There is increasing evidence that this hard measure of success is much more useful than trying to decide whether the tumor is slightly smaller or not. For patients have lived for a long time with slowly growing tumors. We agreed to publish as coauthors. I suggested that the first paper would be by Pauling and Hoffer. This was because it was his original idea to use megadoses of vitamin C and the work I had done was merely to test his conclusions. He was very firm that he would not consider this and insisted it would appear as Hoffer and Pauling. I think he felt that as a clinician who had done the clinical work I should be the senior author. He did not have an MD. Linus Pauling, in my opinion, was the most brilliant humanitarian scientist that ever lived. Over his life time in addition to his two Noble Prizes, he was awarded nearly 40 Honorary degrees, PHD’s and DSc’s. I am sorry he was never given an Honorary MD. His contribution to human health has surpassed that of most physicians. We wrote the paper using his method for analyzing the data and my clinical material. But the Proceedings of the National Academy of Sciences refused to accept the paper. One of the criticisms of our paper came from some rumour which had reached the critic that I had solicited patients to come to be seen implying I had selected only the best prognostic patients. On the contrary I had nothing to do with the selection and I included every patient who had been referred. Eventually we published in the Journal of Orthomolecular Medicine. I am the editor and I could not refuse to accept our work. That original paper was reprinted in the book by Ewan Cameron and Linus Pauling Cancer and Vitamin C. Updated and Expanded. Camino Books Inc, P.O. Box 59026, Philadelphia, PA 19102. 1993. Appendix IX is this report.

We began to write a book. My case load was building very quickly and I published a second paper with Dr. Pauling and several more after that on my own. We finshed most of the book except for much of the detailed clinical material but we could not find a publisher in the United States willing to publish it. The topic was still too controversial. I found a Canadian Publisher, Quarry Press, Kingston, ONT. A few months ago I sent him the completed manuscript. This contains all the original material Dr. Pauling had written dealing with each type of cancer and a presentation of my data based on nearly 800 patients. We concluded in our manuscript that the optimum treatment for cancer today is a combination of xenobiotic and orthomolecular therapy and that treatment must be started as soon as possible. This book will be available in about one year.

Source:  A. Hoffer, Ph.D., M.D., F.R.C.P.(C)


Intravenous Ascorbate as a Chemotherapeutic Agent

leave a comment »

Case histories
We have seen patients with almost every type of solid tumor in our center. Many of them have received IAA (intravenous ascorbic acid), with various degrees of success. Our cases include a patient with cancer of the head of the pancreas who lived for 3.5 years with IAA as sole therapy, resolution of bone metastases in patients with breast cancer, many patients with non-Hodgkin’s lymphoma (none of whom have died from their disease), resolution of primary liver carcinoma tumors, resolution of and reduction in size of metastatic colon carcinoma lesions, and resolution of metastatic lesions and over 3-year survival in patients with widely metastatic ovarian carcinoma. We plan to present a full compilation of cases in another communication.

We have seen only two cases of metastatic renal cell carcinoma, considered a uniformly untreatable disease. Because the results were so dramatic, people with this disease could potentially benefit the most from IAA treatment. Following are those two cases.

Case 1
A 52-year-old white female with a history of renal cell carcinoma was seen in our center for the first time in October, 1996.

In September 1995, shortly after diagnosis of a primary tumor in her left kidney, a nephrectomy was performed. Histology confirmed renal cell carcinoma. No evidence of metastases was found at that time. In March 1996, metastases to the lungs were found on chest x-ray film. In September 1996, a chest x-ray film revealed 4 1- to 3-cm masses in her lungs. One month later there were 8 1- to 3-cm masses in her lungs (7 in right lung, 1 in left).

No new medical, radiation, or surgical therapies were performed prior to her visit to our clinic in October 1996, when she began IAA therapy. Her initial dose was 15 g, which increased to 65 g after 2 weeks, two per week. She was also started on: N-acetyl cysteine (Vitamin Research Products, Carson City, NV), 500 mg 1 p.o., QD; beta-1,3- glucan (a macrophage stimulator, NSC-24, Nutrition Supply Corp., Carson City, NV), 2.5 mg 3 p.o. QD; fish oil (Super-EPA, Bronson Pharmaceuticals, St. Louis, MO; 300 mg eicosatetraenoic acid, 200 mg docosahexaenoic acid), 1 p.o. TID; vitamin C, 9 g p.o. QD; beta-carotene (Beta Carotene 25, Miller Pharmacal Group, Inc., Carol Stream, IL), 25,000 lU. 1 p.o. BID; L-threonine (The Solgar Vitamin Co, Inc., Lynbrook, NY), 500 mg p.o. QD (for a deficiency revealed by laboratory testing of serum); Bacillus laterosporus (Lateroflora, International Bio-Tech U.S.A., San Marcos, CA), 280 mg, 2 p.o. QD for intestinal Candida albicans, inositol hexaniacinate complex (Niaplex, Karuna Corp., Novato, CA; 500 mg niacin, 100 mcg chromium) 2 p.o. QD, and a no-refined-sugar diet.

She continued IAA treatments until June 1997 when another chest x-ray film revealed resolution of 7 of the 8 masses, and reduction in the size of the 8th. According to the medical imaging report, “The nodular infiltrates seen previously in the right lung and overlying the heart are no longer evident and the nodular infiltrate seen in left upper lung field has shown marked interval decrease in size and only vague suggestion of an approximately 1 cm density.”

The patient discontinued IAA treatments in June 1997. She has continued on an oral nutritional support program since that time, and 4 years later was well with no evidence of progression.

Case 2
In December 1985, a mass occupying the lower pole of the right kidney was discovered in a 70-year-old white male. Pathology of the mass after a radical nephrectomy confirmed renal cell carcinoma. He was followed by an oncologist at another clinic. Approximately three months after surgery, the patient’s x-ray film and CT scan showed “multiple pulmonary lesions and lesions in several areas of his liver which were abnormal and periaortic lymphadenopathy.”

In March 1986 the patient was seen in our clinic (1). He decided not to undergo chemotherapy. He requested and was started on IAA, 30 g twice per week.

In April 1986, six weeks after the x-ray film and CT scan studies, the oncologist’s report stated,

“. . . the patient returns feeling well. His exam is totally normal. His chest x-ray shows a dramatic improvement in pulmonary nodules compared to six weeks ago. The periaortic lymphadenopathy is completely resolved… either he has had a viral infection with pulmonary lesions with lymphadenopathy that has resolved or (2) he really did have recurrent kidney cancer which is responding to your vitamin C therapy.”
The oncology report in July 1996 stated, “there is no evidence of progressive cancer. He looks well . . . chest x-ray today is totally normal. The pulmonary nodules are completely gone. There is no evidence of lung metastasis, liver metastasis or lymph node metastasis today, whatsoever.”

In 1986 the patient received 30 g infusions twice-weekly for 7 months. The treatments were then reduced to once per week for 8 more months. For an additional 6 months he received weekly, 15 g IAA infusions.

During and after treatments, the patient reported no toxicities, and his blood chemistry profiles and urine studies were normal.

The patient continued well, and was seen periodically at our clinic until early 1997 when he died, cancer-free, at age 82, 12 years after diagnosis.

Now, our standard approach uses initial infusions of 15, 25 and 50 grams. This allows projecting the dose needed to achieve cytotoxicity.


Cancer-Enabling Enzyme Can Be Blocked Naturally

leave a comment »


A discovery made by Dr. Matthias Rath on how nutrient synergy can halt the cascading series of events that lead to the metastasis of cancer has been recently confirmed by Research done at Copenhagen University and published in the International Journal of Cancer.

The Danish study found that the lack of the enzyme urokinase plasminogen activator (uPA) can stop the spread of cancer, as shown in mice genetically modified to not have the enzyme. The absence of uPA prevents the ability of cancer cells to dissolve collagen and metastasize to other parts of the body, but today there are no pharmaceutical solutions to block uPA.

Dr. Matthias Rath’s research shows that blocking this enzyme can be achieved naturally. In 1992, Dr. Rath published research suggesting the use of amino acid lysine as a natural inhibitor of plasmin and other enzymes (matrix metalloproteinases) involved in collagen digestion. Recently, Dr. Rath and his team of researchers at the Matthias Rath Research Institute in Cellular Medicine, Santa Clara, CA have identified a specific combination of nutrients that can inhibit the activity of collagen dissolving enzymes and stop the spread of cancer cells. Dr. Rath’s research shows that Vitamin C, the amino acids L-lysine and L-proline, and a green tea extract known as Epigallocatechin Gallate (EGCG) work together to synergistically block the spread of cancer cells through connective tissue. In addition, this specific nutrient synergy can reduce new blood vessel formation, which supplies blood to tumors (angiogenesis), inhibit cancer cell replication, and induce a natural “suicide” cycle in cancer cells (apoptosis).

“The most effective way to control cancer is by attacking cancer simultaneously at all four ways it threatens health: its spread, growth, lifespan and survival,” says Dr. Rath.

Dr. Rath’s research, published in scientific journals and presented at many scientific conferences, points the way to a new era in the natural control of cancer, which is both more effective and safer than pharmaceutical methods.

For more information on Dr. Rath’s research, go to

Contact: Rich Greenwood 510-687-2362

Source:  Life Extension Daily News

Written by Tracey

October 14, 2008 at 3:19 am

More on Intravenous Vitamin C

with 2 comments

Cancer has an affinity to vitamin C because a vitamin C molecule is very close to a glucose molecule, and we all should know that cancer has an affinity to glucose.

Linus Pauling, two time Nobel Lauriat, theorized that if we could get enough vitamin C into the blood, that the peroxidization (vitamin C is metabolized into Hydrogen Peroxide) would be great enough to kill cancer cells.

The problem with any theory is it must be tested. All the early tests failed and that was that. However, all the early tests administered vitamin C orally. The problem with orally administered vitamin C is the kidneys easily get rid of the excess as fast as you can absorb it. To get the highest amounts of vitamin C into your blood stream, it must be administered intravenously.

Recent studies published in Canada [Canadian Medical Association Journal, March 28, 2006] have shown IV C to be a very powerful alternative to chemotherapy. Interestingly enough, unlike many medical journals that publish articles about people whose tumors have shrunk during the treatment but succumbed to their cancer, the patient studies in the Canadian journal followed the patients long after their cancer had cleared up.

A 49 year old man with terminal bladder cancer refused chemotherapy, got IV C, cured his cancer and is still alive and cancer free 9 years later.

A 66 year old woman with aggressive lymphoma was treated, cured, and still cancer free ten years later.

A 51 year old woman with kidney cancer that spread to her lungs wasn’t given long to live. However, using the IV C she showed no cancer in her lungs even two years after her treatment ended.

Dr Mark Levine of the National Institutes of Health, in the news lately (Jan 08) for showing how an increase in vitamin C can decrease your chances of a stroke, has also tested IV C on cancer.

In studies published in September, 2005 and March, 2006, Dr. Mark Levine and his colleagues at the NIH published key papers requesting that the role of high-dose intravenous vitamin C therapy in cancer patients be reassessed. They found that when administered intravenously, blood levels of vitamin C could be 50 to 70 times higher than the maximum concentrations achieved with the oral dosage alone. Furthermore, they concluded that the intravenous administration could selectively kill cancer cells (or infectious agents) without harming normal cells. []

Dr Robert Jay Rowen, MD, [Second Opinion Health Alerts] tells us about Dr Chuck Mary ( who has had great success with some highly advanced cancers administering 300 grams of vitamin C daily

Vitamin C does not kill cancer directly. It’s a very intricate and interesting process which I will try to explain. First we must discuss apoptosis.

Apoptosis in normal cells is a “form” of cell death (programmed cell death). When a cell’s DNA is damages, the cell will “commit suicide” in an attempt to keep the damage from reproducing and creating a cancer cell. Your immune system is constantly working to keep you healthy and by  cleaning up and getting rid of cancerous cells. However, before your immune system even has a chance to kick in (because a cell with damaged DNA can become cancer) apoptosis occurs. This is an “automatic” process, one we might say occurs at the lowest level of our immune system.

This lowest level could be equated to a computer program that is built into your computer, or the BIOS or an EPROM (a chip with a program hard coded into it). Cells are programmed to replace themselves when the DNA becomes damaged. The program is found in the gene p53, the tumor-suppressing gene. Before rapid, uncontrolled replication can occur (cancer does this), the p53 gene instructs the cell to undergo programmed cell death, called apoptosis.

In a cancer cell we’ve got a bad program. The damage mutates the p53 gene, which now tells the cells to have at it and they continue to multiply even though the DNA is damaged. The whole system gets out of whack, because everything that is supposed to keep this from happening has mutated, including the genes that would normally turn this off. At this time only your immune system can save you.

Your immune system is only as good as your diet and lifestyle. All of us have cancer cells in our bodies. Every study ever done on corpses turns up cancer cells: millions and millions of cancer cells. A healthy immune system will keep these cells from growing out of control and becoming a clinically recognizable cancer.

Back to apoptosis: apoptosis in a cancer cell is not cancer death. Apoptosis in cancer cells makes the cancer visible to the immune system because, let’s face it, the immune system cannot kill something it cannot see. Apoptosis causes the inside of the cell to flip up and become the outside of the cell. Suddenly, phosphatidylserene, which is supposed to be on the inside of the cell, is found on the outside and this triggers the immune system. Phosphatidylserene is found on the outside of cancer cells, viruses, and old blood cells that need replacing.

With this in mind, now I can show you how vitamin C helps to battle cancer.

Laboratory studies show that vitamin C kills cancer. There are three types of tumor models: the sparse model layer, the dense model layer, and the hollow fiber tumor model. Most of the solid tumors in the body are of the hollow fiber tumor model, with the sparse and dense models being found on the outer layers of the tumor. Studies show that plasma levels of just 200mgs/deciliter (one tenth of a liter) will kill all the cells in the dense and sparse models, but hardly touch the hollow fiber tumor model. At 700mgs/deciliter we get about 50% to 65% live cells remaining in the hollow fiber tumor model.

So, we know that these large doses of vitamin C are cytotoxic, or deadly, to cancer. However, it is hard to maintain this high plasma level of vitamin C and the level sought in IV C treatment is 400mgs/deciliter.

Now for those of you taking mega doses of vitamin C orally, you should know that the most you will ever get into your plasma is about 10mgs/deciliter. To get these higher levels, you must have vitamin C administered intravenously (through a needle directly into your vein).

Back to cancer’s affinity to glucose: cancer draws in vitamin C thinking it is sugar. Cancer needs sugar, and a lot of it, to metabolize. So it draws in the vitamin C hungrily and greedily. When your oncologist tells you that the vitamin C will begin to protect the cancer, s/he is speaking out of ignorance. You might want to give your oncologist a short lesson in biochemistry (and nutrition—the one science your oncologist knows nothing about): at these levels, 400mgs/deciliter, vitamin C is no longer an antioxidant, it is a pro-oxidant. It causes oxidation or medically one would say: vitamin C is peroxidative.

At this point, the cancer is in trouble. It needs to “quench” this peroxidation, but lacks the enzyme catalase needed to convert the peroxide, and an aldehyde is formed that is toxic to the cancer cells.

With repeated treatments, over a period of time, we start to kill the cancer off: the layers on the tumor begin to peel away just like peeling away layers of an onion, until the hollow fiber tumor model is revealed and at this point, the kill rate on these cells lessens, but, the really good news is that the peroxidation causes these cancer cells (in the hollow fiber tumor model) to become apoptotic.

This is where immune stimulants come in; this is where Imm-Kine comes in. Imm-Kine will specifically attack apoptotic cancer cells.

Imm-Kine was originally developed at the Aidan Clinic. The Aidan Clinic has been closed, and the staff have moved to the Bahamas to run the Immuno-Technologies Cancer Clinic.

Now, we have to point out here that getting your plasma levels up to 400mgs/deciliter is a difficult procedure. As we state in our disclaimer, everyone is different. The same dosage in two people can produce very different results. Thus your physician will administer and then test and administer and retest.

One way to avoid any dangerous levels is by using another invention of the Aidan Clinic: IVC-Max.

IVC-Max was designed to make intravenous vitamin C work even better. They have documented their successes at the Aidan Clinic, and using the IVC-Max, to get the same “kill rate” in the hollow fiber tumor model that was realized at 700mgs/deciliter they had to use only 120mgs/deciliter.

This might not seem a very big accomplishment, but in actuality, it is a stupendous feat. For one thing, your physician does not have to worry about giving you a dosage you can’t handle and it takes less testing to get you to a safe level. Let’s face it, if only 120mgs/deciliter is doing the same work as the higher levels, your physician doesn’t have to test as often or be particularly concise; if it turns out that they have you at somewhere between 120mgs/deciliter and 400mgs/deciliter you’re set.

So in the long run, with less testing, it will cost you a lot less and the entire event will be a lot less critical. You can sit back and read those year old magazines knowing you’re safe, you won’t go home and puke out your guts, your hair won’t fall out, and your cancer is going take a beating from substances natural to your system.

Source:  Wellness Directory of Minnesota

Written by Tracey

October 11, 2008 at 2:34 am

Could vitamin C jabs cure cancer? This man says it’s put his prostate tumour into reverse.

with 3 comments

Conductor Denis Vaughan

Conductor Denis Vaughan

A Check-up six months ago revealed Denis Vaughan’s prostate cancer was becoming more active.

Vaughan, an orchestral conductor and one of the driving forces behind the creation of the National Lottery, has had prostate cancer for 12 years.

Because the tumour wasn’t considered aggressive enough for surgery or radiotherapy, his consultant at University College Hospital had agreed on a policy of watchful waiting, while Denis kept it at bay with diet and exercise.

Then, his prostate specific antigen (PSA) score, which measures how active the tumour is, went from 13 to 18.5 ‘and the watching became a bit anxious’.

His oncologist wanted him to take drugs or begin radiotherapy, but Vaughan, who is a strong believer in a natural approach to health, preferred to try a treatment offered by his London GP that involved infusing vitamin C into the bloodstream.

He underwent weekly treatment – with up to 75 grams of vitamin C at a time (the recommended daily amount is 60mg).

The treatment, which cost £100 a time (around $200 US), appears to have worked – after seven weeks, his PSA dropped back down to 13, a level described as moderately elevated, and he’s back on watchful waiting. His oncologist has said he now doesn’t need to see Vaughan for another year.

It’s an unorthodox approach, but one that seems to be backed up by research published earlier this month, which found that injecting large amounts of vitamin C into laboratory mice with aggressive and hard-to-treat tumours, caused the cancers to shrink by between 41 and 53 per cent.

The American study – reported in top science journal Proceedings Of The National Academy Of Sciences – was greeted cautiously by UK cancer experts.

They emphasised that there is no evidence from clinical trials that Intravenous Vitamin C (IVC) is effective in humans.

Experts also say that while the doses seem comparable to the official daily amounts, there is a big difference between injecting the vitamin directly into the bloodstream – circumventing the body’s own defences – and getting it in food or as a pill.

Hundreds of patients in the UK have already received IVC as a treatment for cancer – without apparent side-effects.

Dr Julian Kenyon, a private GP in Harley Street, says: ‘What the American study shows is that when you infuse amounts as high as 4 grams per kilo – the equivalent of around 75 grams for an average adult – vitamin C causes a build up of a chemical called hydrogen peroxide, which destroys the tumour.’

Dr Kenyon has treated more than 100 patients over the past ten years with IVC and claims there is now quite a body of experience about how to use it.

The chief researcher of the American trial, Dr Mark Levine of the American National Institutes of Health, has been investigating vitamin C’s cancer killing abilities for several years.

He’s already shown that it’s effective in a test tube and, two years ago, he published a report on three patients who were treated for serious and advanced cancers and survived far longer that would normally be expected.

‘We now know that the vitamin C gets into tumours in large amounts and that it kills them by causing a build up of hydrogen peroxide.

‘That’s the same stuff that’s used as bleach but cells in your body also use it to defend themselves,’ he says.

In fact, vitamin C is hardly a new anti-cancer treatment.

It was famously used by double Nobel Prize winner Linus Pauling more than 30 years ago, who found that terminal cancer patients treated with vitamin C lived much longer.

However, when his trials were repeated at the prestigious Mayo clinic in America, the researchers found no benefit. Proponents of vitamin C point out the clinic only used oral vitamin C which can work differently.

‘Actually, the finding that vitamin C is a potent anti-cancer substance goes back even further,’ says Dr Steven Hickey, who has researched vitamin C and cancer at Manchester Metropolitan University, and written several books on the history and chemistry of vitamin C.

‘The discovery that hydrogen peroxide kills tumours in mice was made in 1957, and less than ten years later researchers found that vitamin C would selectively kill cancer cells without harming normal cells,’ he says.

Other researchers achieved similar results to Pauling’s, including some in Japan in 1982 and the eminent Canadian psychiatrist Dr Abram Hoffer of Saskatchewan University.

One of the researchers in the latest American study, Jeanne Drisko, professor of orthomolecular medicine at the University of Kansas, is now running human trials to test for safety and tolerability of the treatment in humans, and is also just starting a trial to test it against hepatitis C.

Her unit also currently offers IVC to patients. She says they carefully monitor patients for signs of trouble.

Among those offering the treatment in the UK is Dr Damien Downing, the president of the British Society for Ecological Medicine.

‘The Society has protocols and standard procedures in place and we make it clear that it is an experimental treatment,’ he says.

But everyone agrees that IVC needs more research. The question is, since you can’t patent vitamin C, who is going to pay for it? Not the drug companies.

‘This is just the sort of thing that public money should be spent on,’ says Dr George Lewith, of the University of Southampton, who assesses complementary and alternative medicines for the National Cancer Research Institute.

‘I would be strongly in favour of running a proper clinical trial of IVC as soon as possible.

Source: Daily Mail

Written by Tracey

September 25, 2008 at 6:59 pm

Vitamin C: Comparing Oral vs. Intravenous Use

leave a comment »

Background: Vitamin C at high concentrations is toxic to cancer cells in vitro. Early clinical studies of Vitamin C in patients with terminal cancer suggested clinical benefits, but two double-blind, placebo-controlled trials showed none. However, these studies used different routes of administration. One used the intravenous method, while the other used the oral method of administration.

Objective: To determine whether plasma Vitamin C concentrations vary substantially with the role of administration (the way it is delivered to the body).

Setting: Academic medical center

Participants: 17 healthy hospitalized volunteers

Measurements: Vitamin C plasma and urine concentrations were measured after administration of oral and intravenous doses at a dose range of 0.015 to 1.25 grams, and plasma concentrations were calculated for a dose range of 1 to 100 grams.

Results: Peak plasma Vitamin C concentrations were higher after the administration of intravenous doses than after administration of oral doses – and the difference increased according to the dose.

Vitamin C at a dose of 1.25 grams administered orally produced mean peak plasma concentrations of 134.8 – compared with 885 for intravenous administration.

For the maximum tolerated oral dose of 3 grams every four hours, peak plasma concentrations were measured at 220 – compared with a measurement of 13,400 for intravenous administration of 50 grams through intravenous administration. Urine concentrations of Vitamin C from intravenous administration were 140-fold higher than those with maximum oral doses.

Conclusions: Oral Vitamin C produces plasma concentrations that are tightly controlled. Only intravenous administration of Vitamin C produces high plasma and urine concentrations that might have anti-tumor activity. Because efficacy of Vitamin C treatment cannot be judged from clinical trials that use only oral dosing, the role of Vitamin C in cancer treatment should be re-evaluated.


Written by Tracey

September 25, 2008 at 6:33 pm

Vitamin C Treatment Works!

with 2 comments

Go home and die.   That’s what doctors told 59 year old Arlindo Olivera.

His lung cancer was so advanced, it had spread to his brain and doctors said there was nothing they could do.

Today, Arlindo is cancer free.

Arlindo Oliviera a Lung Cancer Survivor says “My pulmonary doctor told me, whatever you are doing, keep doing it.”

Arlindo believes his cancer is gone because of vitamin C treatment.

Arlindo says “It’s working on me from what the doctor says.”

Dr. Scott Greenberg says he has successfully treated many people with vitamin C infusions, including Arlindo.

Dr. Scott Greenberg a Family Practitioner says “One patient I had had a breast mass from breast cancer that it was literally protruding out of her chest and after a few months of treatment the mass shrunk and went away and it’s been over five years now to where she doesn’t have any sign of cancer whatsoever.”

Some doctors believe vitamin C treatment works by killing the cancer cells.

Researchers at the National Institutes OF Health say it may also work as an anti-oxidant protecting cells from the damage of free radicals.

Dr. Scott Greenberg says “How intravenous vitamin C works for cancer cells is it produces hydrogen peroxide just like chemotherapy does and that hydrogen peroxide will help and cause oxidative damage to the cancer cell thus destroying it.”

The National Institutes OF Health study treated mice with aggressive brain, ovarian and pancreatic tumors.

Tumor growth and weight was reduced by 41 to 53 percent and the brain cancer stopped spreading.

Doctor Greenberg says it only works in very high intravenous doses.  He says it’s a valuable option for those who don’t respond to other treatment.

Arlindo continues to be cancer free.  The treatment is not covered by insurance, but costs considerably less than standard therapies.

Source:  WRCB Channel 3 – Chatanooga, TN

Written by Tracey

September 25, 2008 at 5:41 am